Hematology TimesAnalysis suggests ‘Burkitt-like lymphoma’ is a misnomerMarch 7, 2019B Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology TimesGene expression signature reveals high-grade GCB DLBCLMarch 2, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersTranslational Research
Hematology NewsPriority review granted to lenalidomide for FL, MZLMarch 2, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersAggressive Lymphomas
Oncology PracticeBarriers to CAR T use in the spotlight at first European meetingFebruary 28, 2019Immuno-oncologyImmunotherapyB Cell LymphomaAggressive LymphomasCellular TherapyBusiness of MedicineGene Therapy
Hematology NewsZUMA-1 update: Axi-cel responses persist at 2 yearsFebruary 24, 2019B Cell LymphomaCellular TherapyTransplantationLymphoma & Plasma Cell DisordersImmuno-oncology
Hematology NewsDual-targeted CAR T shows ‘clinical signal’ in NHLFebruary 24, 2019B Cell LymphomaMantle Cell LymphomaCellular TherapyTransplantationLymphoma & Plasma Cell DisordersImmuno-oncology
Hematology NewsHaplo-HCT shows viability in DLBCLFebruary 21, 2019B Cell LymphomaCellular TherapyLymphoma & Plasma Cell DisordersTransplantation
Hematology NewsFDA grants priority review to polatuzumab vedotin for DLBCLFebruary 20, 2019B Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology TimesResearchers characterize new subtype of high-grade DLBCLFebruary 17, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology NewsCAR T-cell therapies difficult to compareFebruary 16, 2019B Cell LymphomaImmuno-oncologyLymphoma & Plasma Cell Disorders
Hematology NewsAdding palbociclib upped responses in previously treated MCLFebruary 15, 2019Mantle Cell LymphomaB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsFew DLBCL patients benefit from nivolumabFebruary 14, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsTargeted triplet shows potential for B-cell cancersFebruary 14, 2019CLLLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationB Cell Lymphoma
Hematology NewsAnthracyclines, bendamustine are options for grade 3A follicular lymphomaFebruary 11, 2019Follicular LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsIbrutinib-MTX-rituximab combo shows promise in CNS lymphomaFebruary 11, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersCNS/Brain CancerB Cell Lymphoma
